TABLE 1.
Treatment with the 1018 ISS reduced and delayed the incidence and progression of disease and increased the survival rate
| Treatmenta | Incidenceb (%) | Progressionc in animals with disease (%) | Timed to symptoms (days) | Survival timed (days) | Survivale (%) |
|---|---|---|---|---|---|
| 2 h, ISS | 9/15 (60)f | 8/9 (89)f | 6.6 ± 0.6g | 12 ± 1.4g | 6/15 (40)f |
| 6 h, ISS | 12/15 (80)f | 10/12 (83)f | 5.7 ± 0.3h | 10.6 ± 1.1h | 4/15 (27)f |
| 6 h, PBS | 15/15 (100) | 15/15 (100) | 4.9 ± 0.2 | 9.5 ± 0.8 | 0/15 |
| None | 15/15 (100) | 15/15 (100) | 4.7 ± 0.2 | 8.1 ± 0.3 | 0/15 |
Intravaginal topical treatments were delivered 2 or 6 h post-viral inoculation as indicated.
Incidence of disease is measured by the development of hair loss and erythema and is expressed as the number of animals with symptomatic disease/number of animals in the group.
Progression, expressed as number of animals with progression of disease/number of animals with disease, can occur in the animals that develop hair loss and erythema and is indicated similarly by neurologic injury manifested by the chronic release of urine.
Mean for animals with disease signs ± SEM.
Survival is presented as the number of animals alive 21 days p.i./number of animals in the group.
P < 0.01 (ANOVA) versus PBS treatment or no treatment.
P < 0.0001 (log rank analysis) versus PBS treatment or no treatment.
P < 0.001 (log rank) versus PBS treatment or no treatment.